REGISTER
Sino Biopharm Licenses to AZ, Takes Over GSK Assets
Sino Biopharm out-licensed COPD asset TQC3721 (PDE3/4 inhibitor) to AZ for $1.9B and took over China commercialization of GSK’s Trelegy and Anoro. TQC3721 is the 2nd global PDE3/4 inhibitor in clinic, showing 194–241 mL FEV1 gains. Trelegy ($4B) and Anoro ($0.7B) strengthen its respiratory portfolio, enabling a unique originator+generics model.

On July 8, Sino Biopharm announced two heavyweight deals in a single day. On one hand, it out-licensed global rights (excluding China) of its self-developed COPD innovative drug TQC3721 (PDE3/4 inhibitor) to global respiratory leader AstraZeneca for up to $1.9 billion. On the other hand, it further deepened its strategic collaboration with GSK, securing exclusive commercialization rights in mainland China for two global heavyweight respiratory drugs—Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol dry powder inhaler) and Anoro Ellipta (umeclidinium/vilanterol dry powder inhaler).

In this "sell one, buy two" maneuver, Sino Biopharm’s strategic blueprint in the respiratory arena is gradually coming into focus.

$1.9 Billion Global Out-Licensing

TQC3721 is an inhaled PDE3/4 dual inhibitor independently developed by Sino Biopharm’s subsidiary Chia Tai Tianqing. Through balanced inhibition of PDE3 and PDE4, it achieves synergistic bronchodilation and anti-inflammatory effects. This mechanism is regarded as the first innovative inhaled formulation in the COPD field in nearly two decades, with global market potential estimated at the tens of billions of dollars.

Before TQC3721, only one PDE3/4 inhibitor had been approved globally—Verona’s ensifentrine. Ensifentrine received FDA approval in June 2024, with post-launch sales exceeding expectations: $36.6 million in Q4 2024, surging to $71.3 million in Q1 2025 (95% QoQ growth), and reaching $488 million in full-year 2025 sales.

TQC3721 is the world’s second and China’s first PDE3/4 inhibitor in clinical development. Results from its Phase II study (PACER-II) showed that at Week 4, the 3 mg dose group achieved a mean peak FEV1 improvement of 194 mL, and the 6 mg dose group achieved 241 mL—differences of 100 mL and 147 mL versus placebo, respectively. Notably, TQC3721’s clinical trials enrolled more GOLD Grade 2 and 3 moderate-to-severe COPD patients, covering a broader COPD population than ensifentrine. TQC3721 also demonstrated BIC potential across multiple dimensions including FEV1 improvement and SGRQ scores, a differentiated advantage that significantly enhances the asset’s valuation.

In terms of formulation strategy, TQC3721 is being developed in parallel as a nebulized inhalation suspension and a dry powder inhaler, adaptable to different patient populations and clinical settings. For COPD, the nebulized suspension is currently in Phase III in China, while the dry powder formulation is advancing through Phase II. If development proceeds smoothly, TQC3721 is expected to become China’s first domestically developed inhaled PDE3/4 dual inhibitor to receive marketing approval.

COPD is the third leading cause of death globally, affecting 500 million patients worldwide; China has approximately 100 million COPD patients, making it the country’s third leading cause of death and accounting for over 30% of global COPD mortality. In July 2025, Merck acquired Verona—a biotech focused on respiratory diseases—for $10 billion, gaining ensifentrine, the world’s first approved PDE3/4 inhibitor, drawing global attention to this therapeutic area.

The domestic PDE3/4 inhibitor landscape features three major players: Chia Tai Tianqing (Sino Biopharm), Hengrui Medicine, and Haisco. In late July 2025, Hengrui out-licensed global rights to its PDE3/4 asset HRS-9821 and up to 11 other innovative projects to GSK for a $500 million upfront payment and up to $12 billion in potential milestones. In January 2026, Haisco licensed HSK39004 to AirNexis. Now, TQC3721—the most advanced among them—has also secured its partnership with AstraZeneca.

A key highlight of this deal lies not only in the financial terms but also in the choice of partner. AstraZeneca is the world’s largest respiratory/immunology player by revenue, with its respiratory/immunology segment generating $8.87 billion in 2025. It has a sales network covering 125 countries and currently maintains over 15 respiratory product candidates, four of which generate over $1 billion in annual sales (e.g., budesonide/formoterol at $2.89 billion in 2025). AstraZeneca is the ideal global partner for TQC3721.

AstraZeneca’s current respiratory pipeline does not include any PDE3/4-targeting inhaled drugs. Its existing core products—including biologics and inhaled formulations—can form a complementary relationship with a PDE3/4 inhibitor, and its well-established global R&D and commercialization network can maximize value realization. Locking in a BIC-potential PDE3/4 inhibitor with a $200 million upfront payment is undoubtedly a highly cost-effective pipeline addition for AstraZeneca.

Taking Over GSK’s Respiratory Assets

On the same day, Sino Biopharm announced a further deepening of its strategic collaboration with GSK, through its core subsidiary Chia Tai Tianqing, to commercialize Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol dry powder inhaler) and Anoro Ellipta (umeclidinium/vilanterol dry powder inhaler) in mainland China. This collaboration will cover over 9,000 hospitals and primary healthcare institutions across mainland China, further improving accessibility of the two drugs.

Trelegy Ellipta is a once-daily, single-inhaler triple therapy containing an inhaled corticosteroid (fluticasone furoate, FF), a long-acting muscarinic antagonist (umeclidinium, UMEC), and a long-acting beta2-agonist (vilanterol, VI), delivered via GSK’s proprietary Ellipta dry powder inhaler. Trelegy was approved in China in 2019 for COPD maintenance therapy, and in January 2026, it received an additional approval for adult asthma maintenance therapy, making it China’s first and only single-inhaler triple therapy approved for both asthma and COPD maintenance. In 2025, Trelegy generated approximately $4 billion in global sales (£3.0 billion), firmly ranking first among global inhaled formulations.

Anoro Ellipta is a dual bronchodilator delivered via the Ellipta dry powder inhaler, consisting of the LAMA umeclidinium and the LABA vilanterol. Anoro was approved in China in 2018 for long-term COPD maintenance therapy and is a core dual-bronchodilator regimen recommended by the GOLD guidelines. In 2025, Anoro generated approximately $700 million in global sales (£542 million).

This is not the first collaboration between the two companies. In May 2026, Sino Biopharm had already entered a strategic collaboration with GSK on bepirovirsen, a functional cure candidate for hepatitis B, with Chia Tai Tianqing responsible for import, distribution, hospital access, and all promotional activities in mainland China. Bepirovirsen is one of the world’s most advanced functional cure candidates for hepatitis B and was granted priority review status by the CDE in April 2026.

In the Chinese market, MNCs’ operating strategies are shifting toward more refined, localized approaches. While mature products have clear clinical value and stable demand, continued deep operation by MNCs themselves may not be the most efficient path—partnering with leading local pharma companies has become a better option. Mike Crichton, President of GSK International, commented on the collaboration, stating that it would integrate GSK’s global expertise in respiratory with Chia Tai Tianqing’s commercial footprint to improve drug accessibility for more patients, while also helping the company better capture opportunities from China’s high-quality development.

Sino Biopharm’s Respiratory Franchise

Respiratory is one of Sino Biopharm’s four core therapeutic areas, alongside oncology, liver disease/cardiometabolic, and surgery/analgesia. The company has built a rich product pipeline spanning nebulized, dry powder, and soft mist formulations, targeting the massive COPD and asthma markets. In 2025, Sino Biopharm’s respiratory/immunology segment generated RMB 2.82 billion in revenue.

On the generic front, Sino Biopharm has launched major products including budesonide inhalation suspension and tiotropium bromide powder inhaler, which have achieved rapid volume growth through national volume-based procurement, becoming foundational treatment options for COPD and asthma in primary care.

Beyond generics, Sino Biopharm has leveraged its proprietary complex inhaled formulation platform to develop multiple improved new drugs, with comprehensive coverage of dual and triple inhaled combination therapies. For example, its self-developed ICS/LABA dual combination TQC3927 and ICS/LAMA/LABA triple combination TQC3302 precisely target the premium inhaled market currently dominated by imported originators such as Trelegy, Anoro, and Bevespi.

By taking over GSK’s originator products, Sino Biopharm has created a unique market dynamic: on the same sales network, it simultaneously operates GSK’s premium originator brands and its own more affordable generic/improved versions of similar products. This tiered product strategy enables multi-dimensional, full-population market coverage against the backdrop of healthcare cost containment and tiered clinical diagnosis and treatment upgrading.

TQC3721 is just one representative of its respiratory innovation pipeline. To date, Sino Biopharm has built a pipeline in respiratory covering cutting-edge targets including TSLP, ST2, and P2X3, forming a clearly tiered product matrix alongside TQC3721.

TQC2731 is a monoclonal antibody targeting TSLP, primarily for type 2 inflammatory diseases including asthma and atopic dermatitis, and is currently in Phase III for indications including severe asthma and chronic rhinosinusitis with nasal polyps. TSLP is one of the most important targets in respiratory and immunology in recent years. To date, only one TSLP mAb—tezepelumab (AstraZeneca/Amgen)—has been approved globally. Among domestic competitors targeting the same target, Sino Biopharm’s TQC2731 initiated Phase III in December 2024, becoming the first domestic TSLP mAb to enter Phase III and leading all domestic same-target candidates, with the potential to become the world’s second and China’s first approved TSLP mAb.

In the targeted therapy space for COPD, Sino Biopharm has also advanced TQC2938 injection, a humanized IgG2 mAb targeting ST2. To date, no biologic targeting ST2 has been approved globally.

For COPD, PDE3/4 inhibitors are better suited for patients with low eosinophil phenotypes characterized by neutrophilic inflammation and frequent exacerbations, while biologics targeting the type 2 inflammatory pathway are only effective in COPD patients with elevated eosinophils (T2 inflammatory endotype). The two classes of drugs act through non-overlapping pathways and can be clinically complementary, covering COPD patients with different inflammatory endotypes.

Conclusion

Indeed, the implementation of a strategic blueprint is never smooth sailing. Competition in the global PDE3/4 therapeutic landscape is intensifying: Merck’s Ensifentrine has already been launched and is rapidly scaling up, while HRS-9821 (developed jointly by Hengrui and GSK) is advancing in parallel. To secure a foothold in the global market, TQC3721 must accelerate its clinical development to seize the optimal launch window while simultaneously reinforcing its differentiated clinical advantages.

From a broader perspective, innovation in China’s respiratory space is just getting started.

0
0
Loading